Who makes AT-527 fed?

AT-527 fed is developed by Atea Pharmaceuticals, Inc..

Last reviewed 2026-04-23 · How we verify

AT-527 fed

Atea Pharmaceuticals, Inc. · Phase 1 active Small molecule

At a glance

Generic name	AT-527 fed
Also known as	Bemnifosbuvir
Sponsor	Atea Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir (PHASE1)
Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a Meal (PHASE1)
Study of AT-527 in Healthy Subjects (R07496998) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AT-527 fed CI brief — competitive landscape report
AT-527 fed updates RSS · CI watch RSS
Atea Pharmaceuticals, Inc. portfolio CI